The deal seeks to bolster the artificial-intelligence offerings of Roche’s diagnostics division, helping to accelerate ...

Upon completion, expected in the second half of the year, PathAI will join Roche's diagnostics division.

PathAI makes AI models that help with the analysis of patient tissue samples and diagnostic tools. Roche has partnered with ...

ZURICH, May 7 (Reuters) - Swiss pharmaceutical giant Roche said on Thursday it had agreed to acquire U.S.-based digital pathology and AI-powered technology firm PathAI in a deal worth $750 million ...

Roche RHHBY said Wednesday it will acquire U.S.-based digital pathology and AI company PathAI in a deal worth up to $1.05 ...

Roche is set to pay out $750 million upfront to acquire digital pathology specialist Path AI in a move by the pharma giant to accelerate the use of artificial intelligence in diagnostic algorithms.

Roche has agreed to acquire PathAI, a Boston-based digital pathology firm, for up to $1.05 billion. Roche plans to pay $750 ...

The agreement could generate an additional $300 million for PathAI if the it leads to the achievement of certain milestones.

Zurich: Swiss pharmaceutical giant Roche announced on Thursday an agreement to acquire US firm PathAI, which specialises in digital imaging and ...

Roche has been working with US AI specialist PathAI for around five years, and has now upgraded that partnership with an offer to buy the company outright for $1.05 billion. Already a giant in the ...

According to the filing, Insight did not pay Roche Diagnostics the money it agreed to pay them by the deadline of April 30.

Roche announced Monday that it is promoting Matt Sause to oversee Roche Diagnostics. Sause currently serves as head of Roche Diagnostics’ North America Region and started his career with the company ...